menu
    • menu

    Company profile for Eleva

    NEW Drugs in Dev: 2
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Eleva Biologics is a clinical-stage biopharmaceutical company pioneering the development of biologics using a proprietary moss-based expression platform. Our innovative pipeline includes therapies for unmet medical needs, such as Factor H for C3 Glomerulopathy (C3G) and a novel treatment for Fabry disease, currently in Phase 1/2 trials. By leveraging our advanced manufacturing technology, we aim to produce complex biologics ef...
    Eleva Biologics is a clinical-stage biopharmaceutical company pioneering the development of biologics using a proprietary moss-based expression platform. Our innovative pipeline includes therapies for unmet medical needs, such as Factor H for C3 Glomerulopathy (C3G) and a novel treatment for Fabry disease, currently in Phase 1/2 trials. By leveraging our advanced manufacturing technology, we aim to produce complex biologics efficiently, delivering transformative therapies to improve patient outcomes worldwide.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ElevaGermany Flag
    Country
    Country
    Germany
    Address
    Address
    Hans-Bunte-Str. 19 79108 Freiburg
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://elevabiologics.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Spyglass Pharma Reports Successful 12-Month Phase 1/2 Trial
    Spyglass Pharma Reports Successful 12-Month Phase 1/2 Trial

    09 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/09/3251760/0/en/SpyGlass-Pharma-Announces-Positive-Topline-12-Month-Phase-1-2-Trial-Results-for-Its-Innovative-BIM-IOL-System.html

    GLOBENEWSWIRE
    09 Mar 2026
    Share Share
    Eleva Initiates Phase 1B Trial For CPV-104 In C3G, Patients
    Eleva Initiates Phase 1B Trial For CPV-104 In C3G, Patients

    21 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/21/3169943/0/en/Eleva-advances-CPV-104-into-Phase-1b-clinical-testing-in-patients-with-C3G-following-the-successful-completion-of-single-ascending-dose-evaluation-in-healthy-volunteers.html

    GLOBENEWSWIRE
    21 Oct 2025
    Share Share
    Eleva Gives 1st Factor H biological Dose in C3-Glomerulopathy
    Eleva Gives 1st Factor H biological Dose in C3-Glomerulopathy

    07 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/07/3110749/0/en/Eleva-administers-first-dose-of-its-Factor-H-biological-treatment-in-C3-Glomerulopathy-to-healthy-volunteers.html

    GLOBENEWSWIRE
    07 Jul 2025
    Share Share
    Eleva Appoints Donato Spota as Chief Financial Officer
    Eleva Appoints Donato Spota as Chief Financial Officer

    13 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/13/3079775/0/en/Eleva-Appoints-Donato-Spota-as-Chief-Financial-Officer.html

    GLOBENEWSWIRE
    13 May 2025
    Share Share
    Eleva & 3PBIOVIAN Sign GMP Manufacturing Alliance
    Eleva & 3PBIOVIAN Sign GMP Manufacturing Alliance

    04 Feb 2025

    // PHARMAWEB

    https://www.pharmiweb.com/press-release/2025-02-04/eleva-and-3pbiovian-sign-strategic-gmp-manufacturing-and-technology-alliance-to-boost-capacity-for-eleva-s-platform-and-pipeline

    PHARMAWEB
    04 Feb 2025
    Share Share
    Eleva Enters Clinical Development of Difficult-To-Express Proteins
    Eleva Enters Clinical Development of Difficult-To-Express Proteins

    12 Oct 2021

    // BIOSPACE

    https://www.biospace.com/article/releases/eleva-enters-clinical-development-of-difficult-to-express-high-potential-proteins/?s=71

    BIOSPACE
    12 Oct 2021
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search